Merck & Co., Inc., proposed acquisition of Seagen

Merck & Co., Inc., is reportedly in negotiations to acquire Seagen Inc (previously known as Seattle Genetics, Inc), with negotiations presently having stalled due to a failure to agree on price.  The acquisition could give Merck & Co., Inc., access to Seagen’s pipeline of antibody-drug conjugates (ADCs). Merck & Co., Inc., has previously announced strategic oncology collaborations with Seagen for two of its ADCs as well as Merck & Co., Inc., taking a USD1B equity stake in Seagen.   Neither Merck & Co., Inc., nor Seagen have made any formal announcement about the purported acquisition.